EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus

Seongmee Jeong iD, Jungryul Kim, Woojin Jung iD, Jiyeon Jeon iD, Hyeongjun Jo, Kyoung-Bin Ryu, Ja-Young Hong, Kwan Soo Kim, Seongjun Yang, Hee Young Ju, Hwi-Yeol Yun iD, Jung-Woo Chae iD und 2 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Seongmee Jeong und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungnam National University, Deajeon, South Korea. Hauptthemen laut MEDLINE: Sirolimus, Models, Biological, Vascular Malformations, Immunosuppressive Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Food and Drug Safety, Chungnam National University, Institute of Information & Communications Technology Planning Evaluation (IITP), National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.

Methods

Prospective study data (seven subjects) were used as the structural model without covariates, while the retrospective study data (21 subjects) were used as the structural model with size and maturation functions for evaluation. The model was assessed using general model‐building criteria, and a bootstrap stepwise covariate modelling method was used to identify relevant covariates. Simulations were performed for various scenarios to determine the optimal dosing regimen for maintaining sirolimus trough concentrations within a specific range. NONMEM software (Version 7.5) with the first‐order conditional estimation method with interaction was used.

Results

The final sirolimus model was developed using a two‐compartment model, which was implemented by a maturation function using postmenstrual age (PMA), allometrically scaled body weight to account for size differences, and haemoglobin as a covariate on clearance. Simulations were conducted to propose an optimal dosing regimen. A once‐daily dose of 0.01–0.1 mg/kg over 1 month maintained the trough concentration within the range of 5–15 ng/mL, taking into account patient‐specific weight and the influence of haemoglobin constrained on PMA. The optimal dose varied by group, within the range of 0.06–0.09 mg/kg.

Conclusions

We developed a robust and reliable PK model of sirolimus for paediatric patients with vascular anomalies. Paediatric optimal dosing regimens should be based on individual growth patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusModels, BiologicalVascular MalformationsImmunosuppressive AgentsHumansFemaleChild, PreschoolMaleChildInfantProspective StudiesDose-Response Relationship, DrugRetrospective StudiesComputer SimulationAdolescentDrug Administration Schedule

Stichwörter der Autor:innen

optimal dosingpaediatricspopulation pharmacokineticssirolimusvascular anomalies

Substanzen

SirolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • College of Pharmacy, Chungnam National University, Deajeon, South Korea.
  • Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, Seoul, South Korea.
  • Senior Health Convergence Research Center, Chungnam National University, Deajeon, South Korea.
  • Graduate School of Clinical Pharmacy, CHA University, Pocheon, South Korea.
  • Clinical Research Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea.
  • Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

ORCID-Profile: Seongmee Jeong, Woojin Jung, Jiyeon Jeon, Hwi-Yeol Yun, Jung-Woo Chae, Soyoung Lee

Förderung

  • Ministry of Food and Drug Safety, Chungnam National University
  • Institute of Information & Communications Technology Planning Evaluation (IITP)
  • National Research Foundation of Korea (NRF)
  • Korea Environmental Industry & Technology Institute (KEITI)
  • Korea Ministry of Environment (MOE)
  • Korea Machine Learning Ledger Orchestration for Drug Discovery Project(K-MELLODDY)
  • Ministry of Health & Welfare and Ministry of Science and ICT
  • Korea Institute of Toxicology (KIT) Research Program

Zitieren

APA

Jeong, S., Kim, J., Jung, W., Jeon, J., Jo, H., Ryu, K. B., Hong, J. Y., Kim, K. S., Yang, S., Ju, H. Y., Yun, H. Y., Chae, J. W., Yoo, K. H., & Lee, S. (2026). Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70595

Vancouver

Jeong S, Kim J, Jung W, Jeon J, Jo H, Ryu KB, et al. Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70595

BibTeX
@article{Jeong2026,
  author = {Jeong, Seongmee and Kim, Jungryul and Jung, Woojin and Jeon, Jiyeon and Jo, Hyeongjun and Ryu, Kyoung-Bin and Hong, Ja-Young and Kim, Kwan Soo and Yang, Seongjun and Ju, Hee Young and Yun, Hwi-Yeol and Chae, Jung-Woo and Yoo, Keon Hee and Lee, Soyoung},
  title = {Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70595}
}
Kostenlos starten →